Clinical Scorecard: CDC Releases 2024-2025 Flu Vaccine Guidance
At a Glance
| Category | Detail |
|---|---|
| Condition | Seasonal Influenza |
| Key Mechanisms | Annual vaccination to prevent influenza infection and its complications. |
| Target Population | All persons ≥6 months without contraindications. |
| Care Setting | Immunization clinics and healthcare settings. |
Key Highlights
- Annual influenza vaccination recommended for all persons ≥6 months.
- Trivalent vaccines will be exclusively available; B/Yamagata omitted.
- High-dose, recombinant, or adjuvanted vaccines preferred for adults ≥65 years.
- Vaccination timing recommended by end of October, continuing while viruses circulate.
- Influenza vaccines can be administered with other vaccines, including COVID-19.
Guideline-Based Recommendations
Diagnosis
Management
- Vaccination with age-appropriate influenza vaccines.
- Specific recommendations for travelers to reduce influenza risk.
Monitoring & Follow-up
- Emergency protocols for severe allergic reactions at vaccination sites.
Risks
- LAIV3 contraindicated in immunocompromised persons and pregnant women.
- Severe allergic reactions can occur regardless of allergy history.
Patient & Prescribing Data
Individuals ≥6 months, including those with egg allergies.
Persons with egg allergy can receive any licensed influenza vaccine.
Clinical Best Practices
- Administer vaccines according to proper storage and handling procedures.
- Monitor for vaccine efficacy and effectiveness, especially in older adults.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
